TY - JOUR
T1 - Amyloid and glucose imaging in dementia with Lewy bodies and multiple systems atrophy
AU - Claassen, Daniel O.
AU - Lowe, Val J.
AU - Peller, Patrick J.
AU - Petersen, Ronald C.
AU - Josephs, Keith A.
N1 - Funding Information:
Dr. Claassen is funded by the American Academy of Neurology, Clinical Research Training grant.
Funding Information:
Dr Josephs receives research from the NIH Roadmap Multidisciplinary Clinical Research Career Development Award Grant (K12/NICHD)-HD49078 (PI), the Morris K. Udall PD Research Center of Excellence NIH/NINDS P50 NS40256 (Co-I), and the Dana Foundation (PI).
PY - 2011/3
Y1 - 2011/3
N2 - Background: Multiple Systems Atrophy (MSA) and Dementia with Lewy bodies (DLB) can present with both REM behavior disorder and severe autonomic dysfunction. In rare occasions, patients with MSA progress to cognitive impairment and even dementia. Positron emission topography (PET) imaging using both the amyloid ligand Pittsburgh Compound B (11C-PiB) and 18 flurodeoxyglucose (18F-FDG) was used to ascertain the presence of amyloid and pattern of glucose metabolic derangement in both disorders. Methods: Patients diagnosed with probable DLB or MSA, with clinical symptoms of either REM Behavior Disorder (RBD), Parkinsonism, or dysautonomia were prospectively identified. All underwent both 11C-PiB and 18F-FDG PET imaging. Statistical comparison between DLB, MSA, and normal controls was performed. Results: Six patients, 3 with DLB, 2 with Parkinson predominant MSA (MSA-P), and 1 with cerebellar predominant MSA (MSA-C) were identified. Increased level of PiB retention was noted in all patients diagnosed with DLB, but was absent in MSA. In those with DLB, glucose hypometabolism corresponded with regions of amyloid presence, and included prefrontal, parietotemporal, occipital and primary visual cortex regions. MSA patients were distinguished by cerebellar glucose hypometabolism. Conclusions: These findings emphasize the distinguishing characteristics between the alpha-synuclein related disorders of DLB and MSA. The absence of amyloid in the cases of MSA is a possible distinguishing characteristic of the disorder.
AB - Background: Multiple Systems Atrophy (MSA) and Dementia with Lewy bodies (DLB) can present with both REM behavior disorder and severe autonomic dysfunction. In rare occasions, patients with MSA progress to cognitive impairment and even dementia. Positron emission topography (PET) imaging using both the amyloid ligand Pittsburgh Compound B (11C-PiB) and 18 flurodeoxyglucose (18F-FDG) was used to ascertain the presence of amyloid and pattern of glucose metabolic derangement in both disorders. Methods: Patients diagnosed with probable DLB or MSA, with clinical symptoms of either REM Behavior Disorder (RBD), Parkinsonism, or dysautonomia were prospectively identified. All underwent both 11C-PiB and 18F-FDG PET imaging. Statistical comparison between DLB, MSA, and normal controls was performed. Results: Six patients, 3 with DLB, 2 with Parkinson predominant MSA (MSA-P), and 1 with cerebellar predominant MSA (MSA-C) were identified. Increased level of PiB retention was noted in all patients diagnosed with DLB, but was absent in MSA. In those with DLB, glucose hypometabolism corresponded with regions of amyloid presence, and included prefrontal, parietotemporal, occipital and primary visual cortex regions. MSA patients were distinguished by cerebellar glucose hypometabolism. Conclusions: These findings emphasize the distinguishing characteristics between the alpha-synuclein related disorders of DLB and MSA. The absence of amyloid in the cases of MSA is a possible distinguishing characteristic of the disorder.
KW - Autonomic diseases
KW - Dementia with Lewy bodies
KW - Multiple system atrophy
KW - PIB PET
KW - Parasomnias
UR - http://www.scopus.com/inward/record.url?scp=79951553759&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79951553759&partnerID=8YFLogxK
U2 - 10.1016/j.parkreldis.2010.12.006
DO - 10.1016/j.parkreldis.2010.12.006
M3 - Article
C2 - 21195652
AN - SCOPUS:79951553759
SN - 1353-8020
VL - 17
SP - 160
EP - 165
JO - Parkinsonism and Related Disorders
JF - Parkinsonism and Related Disorders
IS - 3
ER -